NCT07014878 — Beijing DCTY Biotech Co.,Ltd. cancer immunotherapy trial
A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
Registry record
| Registry ID | NCT07014878 ↗ |
|---|---|
| Lead sponsor | Beijing DCTY Biotech Co.,Ltd. |
| Collaborators | — |
| Phase | Phase 1 |
| Status | Not Yet Recruiting |
| Indication | Colorectal Cancer, Lung Cancer, Pancreatic Cancer |
| Enrollment | 18 participants (target) |
| Start date | 2026-05 |
| Primary completion | 2028-08 (est.) |
| Last registry update | 18 May 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07014878), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07014878?
NCT07014878 (A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors) is registered on ClinicalTrials.gov as Phase 1, sponsored by Beijing DCTY Biotech Co.,Ltd..
Is NCT07014878 recruiting?
As of the 2026-05-18 registry update, NCT07014878 is listed as "Not Yet Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07014878?
The lead sponsor is Beijing DCTY Biotech Co.,Ltd..
What condition does NCT07014878 study?
The registered conditions are Colorectal Cancer, Lung Cancer, Pancreatic Cancer. Primary completion is listed as 2028-08 (estimated).
Are results available for NCT07014878?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07014878.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.